Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- JOURNAL OF CUTANEOUS MEDICINE AND SURGERY24(3) · pp.278 · 2020
- 피인용
- Web of Science 11Scopus 12
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 1.909
- ISSN
- 1203-4754
저자
- 김병수제1저자Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
- Maverakis, EmanualDepartment of Dermatology, University of California School of Medicine, Davis, CA, USA
- Alexanian, ClarieDepartment of Dermatology, University of California School of Medicine, Davis, CA, USA
- Wang, Jenny Z.Department of Dermatology, University of California School of Medicine, Davis, CA, USA
- Raychaudhuri, Siba P.교신저자VA Medical Center Sacramento, Division of Rheumatology Immunology, Mather, CA, USA
초록
Tumor necrosis factor (TNF) inhibitors have been used as an excellent therapeutic option in a variety of chronic inflammatory conditions. However, a recognized significant adverse effect of TNF inhibitor therapy is the increased risk of infections. The influence of TNF inhibitors on the course of coexisting or newly developed viral infections has not been extensively investigated. Therefore, we reviewed the recent publications to highlight the incidence, clinical features, management, and prevention of herpes zoster in patients who are receiving TNF inhibitors.
키워드
herpes zosteranti-TNF therapyTNF inhibitorsTNF antagonistsvaccinationvaricella zoster virusANTI-TNF-ALPHAFACTOR MONOCLONAL-ANTIBODYRHEUMATOID-ARTHRITISPOSTHERPETIC NEURALGIAFACTOR ANTAGONISTSBRITISH SOCIETYRISKINFECTIONSADALIMUMABTUBERCULOSIS
식별자
- Scopus EID
- 2-s2.0-85083277525
- WoS UID
- 000523530900001



로그인
연구물 목록으로